References
- Bhugra D. The global prevalence of schizophrenia. Plos Med. 2005;2:e151;quiz e175.
- Health NIoM. Schizophrenia. What are the symptoms of schizophrenia?. 2010. Available from: http://www.nimh.nih.gov/health/publications/schizophrenia-booklet-12-2015/index.shtml;
- Lin CH, Huang CL, Chang YC, et al. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr Res. 2013;146:231–237.
- Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–136.
- Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.
- Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3:495–500.
- Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry. 2002;181:271–275.
- Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf. 1993;9:429–436.
- Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158:311–314.
- Stroup TS, Al J, Ss M, et al. Comparative effectiveness of antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci. 2000;2:373–379.
- Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892–899.
- Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40:407–414.
- Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S–115S.
- Citrome L, Collins JM, Nordstrom BL, et al. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J Clin Psychiatry. 2013;74:1199–1206.
- Nielsen RE, Levander S, Kjaersdam Telleus G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia–a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131:185–196.
- Brexpiprazole (Rexulti) for schizophrenia and depression. Med Lett Drugs Ther. 2015;57:116–118.
- FDA approves new drug to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder. Edited by Release FN. 2015. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454647.htm;
- Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605–614.
- Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589–604.
- Ishima T, Futamura T, Ohgi Y, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015;25:505–511.
- Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25:356–364.
- Otsuka Pharmaceutical Co. Ltd. REXULTI® (brexpiprazole) US prescribing information. Otsuka Pharmaceutical Co. Ltd.; 2015. Available from: http://otsuka-us.com/products/Documents/Abilify.PI.pdf.
- Otsuka Pharmaceutical Development & Commercialization I: PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia. 2016. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01854944: U.S. National Institutes of Health
- Otsuka Pharmaceutical Development & Commercialization I. Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (STEP 203). 2015. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00905307?term=nct00905307&rank=1§=X40156: ClinicalTrials.gov
- Otsuka Pharmaceutical Development & Commercialization I. Multicenter, Open-label, Safety and Tolerability Study (STEP 210). 2015. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01649557?sect=X9430156: ClinicalTrials.gov
- Otsuka Pharmaceutical Co. L.. A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia. 2015. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01451164: ClinicalTrials.gov
- Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled Trial. Am J Psychiatry. 2015;172:870–880.
- Otsuka Pharmaceutical Development & Commercialization I. Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR). 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01396421?term=NCT01396421&rank=1: ClinicalTrials.gov .
- Montoya A, Valladares A, Lizan L, et al. Validation of the excited component of the positive and negative syndrome scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.
- Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164:127–135.
- Otsuka Pharmaceutical Development & Commercialization I. Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON). 2015. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01393613?term=nct01393613&rank=1: ClinicalTrials.gov
- A/S HL. Brexpiprazole in Patients With Acute Schizophrenia. 2016. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01810380?term=NCT01810380&rank=1§=X340156: ClinicalTrials.gov
- Otsuka Pharmaceutical Development & Commercialization I. Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02013622?term=NCT02013622&rank=1: ClinicalTrials.gov
- Otsuka Pharmaceutical Development & Commercialization I. Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia. 2015. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02054702?term=NCT02054702&rank=1§=X6: ClinicalTrials.gov.
- Harvey RJ, Yee BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013;12:866–885.
- Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100:665–677.
- Freedman R. alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med. 2014;65:245–261.
- Gazdag G, Ungvari GS. Non-pharmacological biological therapies in schizophrenia. Neuropsychopharmacol Hung. 2011;13:233–238.